254 Results
The first presentation of data resulting from a corporate partnership to explore development of a new diagnostic test based on Biodesix’ technology.
Biodesix has closed on a $12 million extension to its Series D financing. The new capital will support commercialization activities for VeriStrat.
Study demonstrates that physicians are using the company’s VeriStrat test to help guide treatment decisions for patients with NSCLC.
Results from two phase II advanced lung cancer trials will be presented at the upcoming 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Data confirms that the blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for 2nd line NSCLC.
Journal of Thoracic Oncology Study: VerStrat provides oncologists with more information to personalize therapy for their patients.
Analysis showed that the VeriStrat test was able to identify patients more likely to have a slower progression of disease with select treatments.
Biodesix’ Paul Beresford will join industry veterans on a panel discussing the recipe for the successful commercialization of personalized medicine.
Dr. Roder will discuss the use of Biodesix’ high throughput mass spectrometry technology, Deep MALDI, to generate protein signatures for Oncology questions.
VeriStrat test was able to identify patients likely to have better and worse survival outcomes when treated with the combination therapy.